Additional information
| Dosage Form | Tablets |
|---|---|
| Specialities | Orthopaedic, Physician |
| Packing | 1 Tab (Alu-Alu) |
| Therapeutic Segment | Osteoporosis |
- Prophylaxis of skelatal events in patients with breast cancer and bone metastases
- Treatment and prophylaxis of post menopausal osteoporosis
- Patients with low BMD
As directed by physician
Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Ibandronate's mechanism of action is to inhibit osteoclast activity, which reduces bone resorption and turnover. This helps bones stay stronger and reduces the risk of fractures.
